Mira Pharmaceuticals received a notice from Nasdaq indicating it no longer meets the minimum bid price requirement of $1 per share due to its closing stock price for 30 consecutive business days ending July 24, 2026. The company has an 180-day compliance period until January 25, 2027, during which the stock must close at or above $1 for ten consecutive trading days. Failure to comply may result in delisting, though the company may seek a second extension and consider a reverse stock split as a remediation option. Mira Pharmaceuticals operates in the pharmaceutical industry.
